1. Home
  2. Directory
  3. Virginia
  4. Dumfries
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1306884549

MICHAEL ALAN SCHWARTZ MD
Prescription History 1306884549
Psychiatry & Neurology - Neurology in Dumfries, VA

NPI Status: Active since June 02, 2006

Contact Information

2204 POTOMAC RIVER BLVD
DUMFRIES, VA
ZIP 22026
Phone: (813) 495-2222
Fax: (571) 231-6663

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MICHAEL ALAN SCHWARTZ MD, an active Neurology specialist practicing in Dumfries, VA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 90 documented patient claims. Among these therapy options, the most frequently utilized medication is Gabapentin, which accounts for 27 claims alone.

Medication Index

D
G
L
P
No matching medications currently found on file.

Donepezil Hcl

Generic Formulation: Donepezil HclSpecialty: Neurology
Provider Metrics Summary
Total Claims 18
30-Day Fills 45.0
Days Supply 1,350
VA State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills87.0
Peer Average Days Supply2,547
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.0% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $320.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.83

State Avg Cost Per Claim

$18.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Donepezil is used to treat confusion (dementia) related to Alzheimer's disease. It does not cure Alzheimer's disease, but it may improve memory, awareness, and the ability to function. This medication is an enzyme blocker that works by restoring the balance of natural substances (neurotransmitters) in the brain.

Gabapentin

Generic Formulation: GabapentinSpecialty: Neurology
Provider Metrics Summary
Total Claims 27
30-Day Fills 45.0
Days Supply 1,350
VA State Average Benchmarks
Peer Average Claims89.0
Peer Average 30-Day Fills132.3
Peer Average Days Supply3,808
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.7% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $634.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.51

State Avg Cost Per Claim

$19.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Lacosamide

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 400
VA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills34.9
Peer Average Days Supply947
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,575.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$183.99

State Avg Cost Per Claim

$310.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 32.0
Days Supply 960
VA State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills68.8
Peer Average Days Supply1,989
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.4% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $630.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.00

State Avg Cost Per Claim

$44.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Pregabalin

Generic Formulation: PregabalinSpecialty: Neurology
Provider Metrics Summary
Total Claims 17
30-Day Fills 29.0
Days Supply 870
VA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills53.6
Peer Average Days Supply1,556
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.5% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,220.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$71.79

State Avg Cost Per Claim

$47.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.

Therapeutic Applications

This medication is used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, or spinal cord injury. This medication is also used to treat pain in people with fibromyalgia. It is also used with other medications to treat certain types of seizures (focal seizures).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MICHAEL ALAN SCHWARTZ MD provides transparency into local medical care patterns within Dumfries, VA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.